Keytruda made available on the NHS for certain oesophageal cancer patients

17 September 2021 - NICE has recommended MSD’s Keytruda (pembrolizumab) combined with chemotherapy for the first-line treatment of certain oesophageal ...

Read more →

BioCryst’s HAE med Orladeyo wins NICE nod

16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary ...

Read more →

NICE backs Opdivo for head and neck cancer

15 September 2021 - NICE has recommended Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for routine use on the NHS ...

Read more →

UK terminates Valneva COVID-19 vaccine supply agreement

13 September 2021 - The UK government has terminated its supply agreement with French firm Valneva for its COVID-19 vaccine ...

Read more →

NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug

10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...

Read more →

MHRA statement on booster doses of Pfizer and AstraZeneca COVID-19 vaccines

9 September 2021 - The regulatory changes made by the MHRA today give further options for the deployment programme. ...

Read more →

MHRA approves Amgen’s Lumykras under Project Orbis

10 September 2021 - Amgen has announced that is first-in-class KRAS G12C inhibitor Lumykras (sotorasib) has been received a conditional ...

Read more →

UK approval for Pfizer’s JAK inhibitor Cibinqo

10 September 2021 - The UK MHRA has approved a marketing authorisation for Pfizer’s oral Janus kinase 1 inhibitor Cibinqo ...

Read more →

NICE recommends treatment for people with juvenile idiopathic arthritis

9 September 2021 - NICE has today published final draft guidance which recommends tofacitinib (Xeljanz; Pfizer) as an option for treating ...

Read more →

Albireo receives UK MHRA approval of Bylvay (odevixibat)

8 September 2021 - Bylvay now approved in U.S., EU and UK as first drug treatment for patients with progressive familial intrahepatic ...

Read more →

Nivolumab scores a rare 'no' from NICE

8 September 2021 - Nivolumab scores only its second final rejection to date from NICE. ...

Read more →

NICE draft guidance recommends apalutamide for treating prostate cancer

8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...

Read more →

UK MHRA grants GenSight Biologics’ Lumevoq ophthalmic gene therapy Promising Innovative Medicine Designation

6 September 2021 - GenSight Biologics today announced that its gene therapy Lumevoq has been granted Promising Innovative Medicine designation by ...

Read more →

GSK’s shingles vaccine Shingrix gains UK license

2 September 2021 - GlaxoSmithKline's Shingrix has been licensed in the UK for the prevention of shingles in adults aged ...

Read more →

NICE recommends Novartis’ Cosentyx for children with severe psoriasis

3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people ...

Read more →